Medicines for Europe

🌱 New environmental regulations must strike a balance between sustainability targets and the need to maintain #access to affordable medicines. 🔁 Support our call for #EUCriticalHealth!

Register during the Green Week for the #Biosimilar Medicines Conference on 3-4 April 2025 in Amsterdam and get 15% discount! ➡️ https://lnkd.in/dUsxCBBf Deadline to get the discount and arrange the payment: 15 November Hotel booking form: https://lnkd.in/eSDruYVt More info on https://lnkd.in/dsVJNVTq #BIOS25 #biosimilars #GBW24 #Globalbiosimilarsweek Medicines for Europe, Adrian van den Hoven, Julie Marechal-Jamil, Mina Grguri, Trudy Beks, Cristina Romagnoli, Kate O'Regan, Erika Zavan

✅ Health security depends on off-patent medicines. To ensure access to essential medicines, our industry advocates for a #CriticalMedicinesAct that supports investment in manufacturing technologies and digital tools. 🌐 Let's embrace digital solutions to meet critical EU health challenges! 🤝 🔁 Show your support, and join #EUCriticalHealth!

Join us in our webinar "Streamlining the Regulatory Process to Advance Access to Biosimilars", happening next week, on 13 November! The webinar will focus on hashtag Streamlining Regulatory Requirements to advance access to biosimilars and will feature expert discussions on the key barriers to biosimilar uptake in different regions and explore strategies to overcoming these obstacles. You can find the registration link here: https://lnkd.in/eQgBx7f3

📣 The adoption of the Urban Waste Water Treatment Directive threatens to trigger a wave of essential and critical medicine #shortages across Europe. 🔄 If implemented as is, the directive will impose enormous financial burdens on the off-patent medicines sector, risking severe disruptions in #access to life-saving treatments. Off-patent medicines represent 7 out of 10 dispensed medicines and 9 out of 10 critical treatments. These include essential medications for cardiovascular disease, cancer, diabetes and many other conditions. We are committed to exploring all options to correct the course of this directive and protect #patients from the looming shortage crisis. 🔗 Read more in our PR: https://buff.ly/3NUEhbi

Register NOW for the 3rd Bioequivalence Conference in Amsterdam! https://lnkd.in/dqptZ2RF More details on https://lnkd.in/df4S3d-6 See you in Amsterdam! #BIOEQ25 #Genericmedicines #pharmaceuticallegislation #shortages #Internationalharmonisationbioequivalence #ICHM15Guideline Medicines for Europe, Adrian van den Hoven, Beata Stepniewska, Trudy Beks, Cristina Romagnoli, Erika Zavan, Kate O'Regan, Beatriz S., Liana Petrosova, Loreleï L., Indiana Castro IGBA - International Generic and Biosimilar medicines Association, Susana Almeida, Nicolas Tascon G., Carlotta Cogoni

🌍 Join us for the upcoming #GlobalBiosimilarsWeek 2024! 📅 Next November 11-15, share your stories, information and educational resources on the value of #BiosimilarMedicines. 🤝 Patients, healthcare providers, regulators or industry professionals - this is your chance to join the conversation and discuss the impact of #BiosimilarMedicines. 🧪 Our theme this year, 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬, focuses on how these medicines are improving access to safe, effective and affordable treatments worldwide. 👥 Share your stories and read more here: https://buff.ly/48BNNcJ #GBW24 #TogetherforBiosimilars #MedicinesforEurope IGBA - International Generic and Biosimilar medicines Association

📣 Today, hearings for the Commissioners-designate begin at the European Parliament. 🗣️ We call on the Commissioner for Health to address #CriticalMeds, timely and equitable #access for patients and secure supply chains to provide affordable treatment for #patients. Let’s strengthen our #EuropeanHealthUnion! 🤝 ➡️ Read more: https://buff.ly/40xyQ9Q ➡️ Read our manifesto: https://buff.ly/3NRdJHJ

🗣️ The EU must ensure timely and equitable #access to off-patent medicines after IP expiry for millions of #patients. 9 out of 10 products on the EU's critical medicines list are off-patent medicines. Yet, disparities in access across countries threaten public health as chronic diseases rise. 📈 Together, we should focus on: 🌱 Sustainable access & competitive market policies 💼 Swift adoption of the #PharmaLegislation for affordable off-patent medicines 🏭 EC first #100Days adoption of a #CriticalMedicinesAct 🧪 Investment in the EU as a global leader in #BiosimilarMedicines Let’s work for a stronger #EuropeanHealthUnion! 🤝 ➡️ Read more: https://buff.ly/4e5Ct9R ➡️ Check our manifesto: https://buff.ly/48gRX9S #MedicinesForEurope #Access4All

🚀 Today, we are launching our report on #MarketAccess barriers faced by EU generic and biosimilar pharmaceutical companies in key third-country markets. 🌍 We examined 11 countries with varying socio-economic statuses, trade relationships with the EU and geographic locations. While there are many barriers to trade in pharmaceuticals, our report specifically highlights: 🔹 Public procurement rules 🔹 Regulatory assessments & lack of standard harmonisation 🔹 Local manufacturing preferences 🔹 Local pricing & reimbursement rules 🔹 IP rules Check it out and discover the challenges and opportunities for the off-patent medicines sector in select international markets! 📊 Read our report: https://buff.ly/3O7RkGx Read our PR: https://buff.ly/3YvMMhA #MedicinesForEurope #Access4All